Analysts think CTMX stock price could increase by 82%
Oct 09, 2025, 11:25 AM
8.01%
What does CTMX do
CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
9 analysts think CTMX stock price will increase by 81.60%. The current median analyst target is $6.12 compared to a current stock price of $3.37. The lowest analysts target is $3.54 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.